Sharemaestro company-news research for Eli Lilly and Company (LLY), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
BUE
Argentina
Provisional evidence
Company news sentiment
Latest LLY news and sentiment
Eli Lilly and Company
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
33 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone60/100
→
Published 30-day score52/100
Latest source headline
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
finance.yahoo.com · 30 Sep 2026 22:00
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
33 current stories are mapped specifically to LLY.
What limits the score
Only 1 publisher currently contribute to the measured read.
The stories agree, but freshness-weighted evidence is only 0.159.
Confidence is 22/100, below the threshold for a firm score.
52/100
News scoreEarly balanced news score
22/100
Confidencethin evidence
78%/100
Company news33 company stories
95/100
Story agreement5/100 difference
News history
Daily score and story count over 30 days
02 Sep17 Sep01 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence3
0.159 after freshness weightingSource breadth20
1 independent publishersCompany relevance78
share tied directly to this companyFreshness61
recency-weighted evidenceAgreement95
how closely stories agreePublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks15 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
03 Apr30 Jun25 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
25 Sep 202655ARS 34300.0+4.1%
18 Sep 202657ARS 32940.0+3.3%
11 Sep 202653ARS 31880.0-1.8%
04 Sep 202653ARS 32480.0-2.9%
28 Aug 202652ARS 33440.0-6.4%
21 Aug 202658ARS 35740.0+7.6%
14 Aug 202662ARS 33220.0-0.6%
07 Aug 202664ARS 33414.458812+3.5%
Provisional evidence
News subjects
What is shaping the score
Market update5122 stories · 67%
Earnings505 stories · 15%
Deals and strategy523 stories · 9%
Regulatory and legal562 stories · 6%
Guidance681 stories · 3%
Source mix
Where the evidence comes from
finance.yahoo.com5333 stories · 100%
Recurring subjects
Subjects appearing most often
Pharma17Earnings12Fda Approval8Diabetes8Clinical Trials8Obesity7Earnings Growth7Biotech6Price Target4Healthcare4
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
07 Aug50 neutral01 Oct 03:56
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 01 Oct 03:56 | 50 | +0 | 34/100 (0) | 81 (-1) | Provisional |
| 30 Sep 23:59 | 50 | -2 | 34/100 (+1) | 82 (-7) | Provisional |
| 29 Sep 23:59 | 52 | -2 | 33/100 (+4) | 89 (+1) | Provisional |
| 28 Sep 23:59 | 54 | -1 | 29/100 (-3) | 88 (-5) | Provisional |
| 26 Sep 23:59 | 55 | +0 | 32/100 (-2) | 93 (-1) | Provisional |
| 25 Sep 23:59 | 55 | +0 | 34/100 (-3) | 94 (-4) | Provisional |
| 24 Sep 23:59 | 55 | +0 | 37/100 (+1) | 98 (0) | Provisional |
| 23 Sep 23:59 | 55 | +0 | 36/100 (0) | 98 (-4) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 33 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Regulatory and legal1 story
0.0%45.5%
Guidance1 story
0.0%32.2%
Deals and strategy2 stories
0.0%20.3%
Earnings1 story
0.0%1.4%
Market update2 stories
0.0%0.5%
Each side uses the same scale: 0–45.5% of the retained directional evidence.
Where the influence comes from
100.0%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Financing co-led by Alpha Wave and YK Bioventures, with participation from Eli Lilly and Company, Gaorong Ventures and existing investors ARCH Venture Partners, Khosla Ventures and Future Ventures Proceeds will advance Moonwalk's lead obesity program into the clinic and accelerate a pipel…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Financing co-led by Alpha Wave and YK Bioventures, with participation from Eli Lilly and Company, Gaorong Ventures and existing investors ARCH Venture Partners, Khosla Ventures and Future Ventures Proceeds will advance Moonwalk's lead obesity program into the clinic and accelerate a pipeline of adipose-selective RNAi medicines targeting novel biology Dr. Stephen Djedjos appointed Senior Vice President, Clinical Development SOUTH SAN FRANCISCO & SAN DIEGO, September 08, 2026--(BUSINESS WIRE)--Moonwalk Biosciences, a biotechnology company developing first-in-class adipose-targeted RNA interferen
- Published
- 08 Sep 2026 12:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 22.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechCardiometabolic DiseasesClinical TrialsObesityRna Therapy
57/100 tone
A month has gone by since the last earnings report for Eli Lilly (LLY). Shares have lost about 2.7% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Lilly due for a b…
1.4% of directional evidence
Low story strength
Scoring detailsDirect company coverage
A month has gone by since the last earnings report for Eli Lilly (LLY). Shares have lost about 2.7% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Lilly due for a breakout? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent drivers for Eli Lilly and Company before we dive into how investors and analysts have reacted as of late. Q2 Earnings Beat, Sales Guidance Raised Lilly reported second-quarter 2026 adju
- Published
- 04 Sep 2026 15:30
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 29/100
- 30-day weight
- 1.4% of directional evidence · 26.6d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsEarnings Per ShareEarnings ReleaseEarnings ReportEstimate RevisionsLarge Cap Pharmaceuticals
60/100 tone
Deals and strategy
What Does Eli Lilly (LLY) Gain From Its $2.88 Billion Immunology Deal?
Eli Lilly (NYSE: LLY) agreed to acquire Merida Biosciences in a deal valued at up to US$2.88b to expand its immunology pipeline. The transaction brings Merida's platform for selectively degrading pathogenic autoantibodies while maintaining normal immune function into Lilly's portfolio. Me…
4.7% of directional evidence
Low story strength
Scoring detailsDirect company coverage
Eli Lilly (NYSE: LLY) agreed to acquire Merida Biosciences in a deal valued at up to US$2.88b to expand its immunology pipeline. The transaction brings Merida's platform for selectively degrading pathogenic autoantibodies while maintaining normal immune function into Lilly's portfolio. Merida's lead autoimmune and allergy candidate is in Phase 1 and is expected to support Lilly's move beyond its established focus on diabetes and obesity therapies. For readers looking to explore more companies pursuing next generation drug discovery and treatment platforms, a focused set of related stocks is av
- Published
- 03 Sep 2026 17:06
- News subject
- Deals and strategy
- Why this score
- Business expansion
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 34/100
- 30-day weight
- 4.7% of directional evidence · 27.5d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
AcquisitionAutoimmune DiseasesBalance SheetImmunologyM APharma
Earlier company news
LLY news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 75 older LLY headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to LLY, but the headline and available text are not mainly about Eli Lilly and Company. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of LLY sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.